1-(3-methylphenyl)-N-(2-pyridinylmethyl)-4-pyrazolo[3,4-d]pyrimidinamine

1-(3-methylphenyl)-N-(2-pyridinylmethyl)-4-pyrazolo[3,4-d]pyrimidinamine, also known as **GSK2881073**, is a potent and selective inhibitor of **Janus kinase 3 (JAK3)**.

**Why it's important for research:**

* **JAK3 Inhibition and Immune Regulation:** JAK3 is a crucial enzyme involved in the signaling pathways of various immune cells, particularly T cells and natural killer cells. Its inhibition has been shown to suppress immune responses, making GSK2881073 a potential therapeutic target for autoimmune diseases and organ transplant rejection.
* **Autoimmune Disease Treatment:** GSK2881073 has been studied extensively in clinical trials for the treatment of **rheumatoid arthritis**, **psoriasis**, and **Crohn's disease**. Its selectivity for JAK3 over other JAK kinases makes it a promising candidate for minimizing adverse effects often associated with broader JAK inhibition.
* **Organ Transplantation:** Inhibiting JAK3 can also help prevent graft rejection in organ transplantation. GSK2881073 is being investigated for its potential to improve graft survival and reduce the need for immunosuppressive drugs.
* **Cancer Research:** JAK3 is implicated in the development and progression of some cancers. While its role in cancer is not fully understood, GSK2881073 and other JAK3 inhibitors are being explored as potential anticancer agents.

**Further Research and Development:**

While GSK2881073 has shown promising results in early clinical trials, its development is ongoing. Researchers are investigating its long-term efficacy, safety, and optimal dosage for different conditions.

**Note:** It's important to understand that GSK2881073 is still in clinical development and is not currently approved for any therapeutic use.